Adapting Healthcare M&A to Uncertain, Complex, and Tech-Driven Growth

Healthcare mergers and acquisitions (M&A) in Europe are experiencing significant changes. The landscape is moving towards more intricate deals and a rise in technology-driven growth. Investors are now facing a new environment, characterized by rapid exits, complex platform-building strategies, and tech-driven deal-making dynamics.

Houlihan Lokey, a key player in recent notable transactions, such as DHG’s combination with Invacare, EMZ’s sale of FotoFinder to GHO, Adelis’ sale of Europa Biosite to EQT, and MidEuropa’s exit from Optegra to EssilorLuxottica, is at the forefront of these developments. Paul Tomasic, Houlihan Lokey’s Head of European Healthcare, sheds light on the emerging trends shaping the industry, the evolution of platform-building strategies, and the critical role of technology in reshaping healthcare services.

One significant trend in healthcare M&A strategy is the increasing influence of technology on investment decisions. Previously, the focus was on traditional buy-and-build strategies, acquiring small platforms at low valuations, aggregating them into larger entities, and selling at a profit. However, with rising debt costs and intensified competition for bolt-on acquisitions, the landscape has shifted. Organic growth has become paramount, necessitating a shift towards technology-driven solutions to boost revenues. Technology now plays a crucial role in enhancing operational efficiency and increasing patient throughput, as seen in ophthalmology clinics like Optegra.

Tomasic emphasizes that technology’s role in healthcare is not solely about cost reduction but also about driving revenue growth. By leveraging technology to optimize processes and enhance patient care, healthcare providers can improve operational efficiencies and profitability. This shift towards tech-driven solutions is reshaping the traditional M&A landscape, requiring investors to adapt to a new paradigm where technological innovation is a key differentiator in deal-making strategies.

Overall, the European healthcare M&A sector is witnessing a transformation characterized by a greater emphasis on technology, complex deal structures, and evolving investment strategies. As investors navigate this dynamic landscape, embracing innovation and technology adoption will be crucial for driving growth and staying competitive in an increasingly uncertain and complex market.